SCHEDULE 13G/A: Venrock Healthcare Capital Partners Group Discloses 9.9% Stake in Cidara Therapeutics

An amended Schedule 13G filing reveals that Venrock Healthcare Capital Partners and its affiliated entities collectively hold a 9.9% beneficial ownership stake in Cidara Therapeutics, Inc. as of March 31, 2025.

Summary

• Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Y Koh (collectively, the "Reporting Persons") have filed an amended Schedule 13G.
• The Reporting Persons collectively beneficially own 1,098,996 shares of Common Stock of Cidara Therapeutics, Inc.
• This aggregate ownership represents 9.9% of Cidara Therapeutics' outstanding Common Stock, rounded down from 9.99% due to EDGAR filing system limitations.
• The beneficial ownership includes 181,702 shares of Common Stock and pre-funded warrants exercisable for up to 159,722 shares held by VHCP III.
• It also includes 18,190 shares of Common Stock and pre-funded warrants exercisable for up to 15,991 shares held by VHCP Co-Investment III.
• Additionally, 851,626 shares of Common Stock and pre-funded warrants exercisable for up to 748,607 shares are held by VHCP EG.
• A "Beneficial Ownership Blocker" provision in the pre-funded warrants prevents the exercise of warrants if it would result in the Reporting Persons owning more than 9.99% of the Issuer's outstanding Common Stock.
• The 9.99% beneficial ownership percentage is calculated based on 10,953,490 shares of Common Stock outstanding as of February 27, 2025, plus 47,478 shares of Common Stock issuable upon the exercise of the pre-funded warrants (the portion that can be exercised without exceeding the blocker).

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or future prospects.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant passive ownership by an investment group in a biotechnology company. It does not provide specific insights into broader industry trends or competitive positioning beyond the fact that a notable healthcare-focused investment firm maintains a substantial stake in Cidara Therapeutics.

Related Party Transactions

• The filing details the beneficial ownership of Cidara Therapeutics' common stock by a group of related entities and individuals (Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Y Koh) who are acting as a group for reporting purposes.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional ownership stake, which can influence market perception and liquidity.
• Investors: Offers insight into the holdings of a prominent healthcare-focused investment group, potentially signaling confidence or strategic interest in Cidara Therapeutics.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Cidara Therapeutics, Venrock Healthcare Capital Partners, Common Stock, Pre-Funded Warrants, SEC Filing, Institutional Ownership, Biotechnology, Pharmaceuticals